文献速递关节外科

口服与静脉及局部氨甲环酸在初次全髋关节置换术中的比较:一项前瞻性、随机、双盲、对照研究

Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study.
PubMed 文献 · J Arthroplasty · 2017-10-06

该前瞻性随机双盲对照试验将180例初次全髋关节置换术患者分为口服(术前2小时口服2克氨甲环酸)、静脉(切皮前5分钟静脉推注20毫克/千克氨甲环酸)和局部(局部应用2克氨甲环酸)三组,主要结局为血红蛋白下降量。结果显示三组血红蛋白下降量及总失血量无显著差异,口服组氨甲环酸费用最低(480元 vs 静脉组3329.28元 vs 局部组3540元,P=0.01),无深静脉血栓、肺栓塞或感染发生。作者认为口服氨甲环酸血液保护效果与静脉及局部相当,推荐口服因其成本效益优势和给药方便。

要点

  • 口服、静脉和局部氨甲环酸三组血红蛋白下降量相似,总失血量无显著差异。
  • 口服组氨甲环酸费用最低(480元),显著低于静脉组(3329.28元)和局部组(3540元),P=0.01。
  • 三组均无深静脉血栓、肺栓塞或感染发生,口服氨甲环酸被推荐因其成本效益和给药方便。

核心结论

  • 口服氨甲环酸的血液保护效果与静脉和局部剂型相当。
  • 作者推荐口服氨甲环酸,因其成本效益优势和给药方便。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照试验。
  • 180例初次全髋关节置换术患者随机分为口服、静脉和局部氨甲环酸三组。
  • 口服组术前2小时口服2克氨甲环酸;静脉组切皮前5分钟静脉推注20毫克/千克氨甲环酸;局部组局部应用2克氨甲环酸。
  • 主要结局为血红蛋白下降量;次要结局包括失血量、输血率、氨甲环酸费用(人民币元,2017年1元=0.147美元)和不良事件。

主要发现

  • 口服组、静脉组和局部组平均血红蛋白下降量分别为3.48±1.32、3.58±1.07和3.66克/分升,组间相似。
  • 三组平均总失血量无显著差异。
  • 口服组氨甲环酸费用最低(480元),静脉组为3329.28元,局部组为3540元,P=0.01。
  • 无患者发生深静脉血栓、肺栓塞或感染。

关键数值与推荐

  • 口服组氨甲环酸费用480元 vs 静脉组3329.28元 vs 局部组3540元(P=0.01)。
  • 血红蛋白下降量:口服组3.48±1.32克/分升 vs 静脉组3.58±1.07克/分升 vs 局部组3.66±1.26克/分升。

临床怎么用

  • 作者推荐口服氨甲环酸,因其成本效益优势和给药方便。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) has demonstrated efficacy in reducing blood loss, reduction in hemoglobin, and blood transfusion requirements in primary total hip arthroplasty (THA). The optimal mode of TXA administration for patients undergoing primary THA is unclear. The purpose of this randomized controlled trial is to determine whether oral administration of TXA was superior to intravenous or topical routes in these patients. METHODS: In this double-blinded, placebo-controlled trial, patients undergoing primary THA were randomized to oral (2 g TXA orally 2 hours preoperatively), intravenous (20 mg/kg intravenous TXA bolus 5 minutes before the incision), or topical (2 g TXA applied topically) TXA groups. The primary outcome was the reduction in hemoglobin. Secondary outcomes included blood loss, transfusion rate, cost of TXA (Chinese yuan (¥); in 2017, ¥1 = $0.147), and adverse events. RESULTS: One hundred eighty patients were randomized into the 3 groups. Demographic characteristics were similar among the groups. The mean reduction in hemoglobin was similar among the oral, intravenous, and topical groups (3.48 ± 1.32, 3.58 ± 1.07, and 3.66 ± 1.26 g/dL, respectively). Similarly, the mean total blood loss did not differ significantly among the 3 groups. The oral group incurred the lowest TXA cost (¥480) compared with that in the intravenous (¥3329.28) and topical (¥3540) groups (P = .01). None of the patients sustained a deep venous thrombosis, pulmonary embolism, or an infection. CONCLUSION: The blood-sparing efficacy of oral TXA is comparable to that of the intravenous and topical forms. Oral TXA is recommended because of its cost-benefit superiority and ease of administration.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Luo ZY, Wang HY, Wang D, et al. Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study. J Arthroplasty. 2017. PMID: 29107495. doi:10.1016/j.arth.2017.09.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。